Fresenius Kabi Australia

Company snapshot

Welcome to Fresenius Kabi Australia and New Zealand. Fresenius Kabi is a global healthcare company that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Our product portfolio comprises of a comprehensive range of I.V. generic drugs, infusion therapies,

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Fresenius Kabi Australia. Not investment advice.

• What is Fresenius Kabi Australia?

  Fresenius Kabi Australia is a pharma organization headquartered in Mount Kuring-Gai, AU. Primary therapeutic focus areas include Hypovolemia, Pruritus, Chronic Kidney Diseases, Chronic inflammatory diseases. NovaPharmaNews links 5 clinical program(s), 2 drug profile(s), and 0 pat

• Is Fresenius Kabi Australia publicly traded?

  Fresenius Kabi Australia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Fresenius Kabi Australia develop or market?

  We link 6 drug profile(s) where Fresenius Kabi Australia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/fresenius-kabi-deutschland-gmbh#company-drugs.

• What are the latest developments for Fresenius Kabi Australia?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Fresenius Kabi Australia focus on?

  Fresenius Kabi Australia focuses on Hypovolemia, Pruritus, Chronic Kidney Diseases, Chronic inflammatory diseases based on our analysis of their pipeline programs and drug development activities.